Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023)

Bioventus' (BVS) quarterly Cash from Discontinued Operations came in at 2169000.0 in Q2 2023, down 70.65% on a QoQ basis from 1271000.0 in Q4 2022.

Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023) Analysis & Trends

Bioventus (BVS) has 2 years of Cash from Discontinued Operations data on file, last reported at 2169000.0 in Q2 2023.

Quarterly Cash from Discontinued Operations changed N/A year-over-year to 2169000.0 in Q2 2023, while the trailing twelve-month figure through Dec 2023 was 2169000.0 (down 1.83% YoY) and the FY2023 annual result came in at 2169000.0, down 1.83% from the prior year.
Cash from Discontinued Operations eased to 2169000.0 in Q2 2023, from 1271000.0 in the prior quarter.
In the past five years, Cash from Discontinued Operations ranged from a high of 859000.0 in Q4 2022 to a low of 2169000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Discontinued Operations (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	-
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	-
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	-
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	-
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	-
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	-
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	-
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	-
10	Bioventus	972.56 Mn	943.11 Mn	105.67 Mn	-

Download Data